Oh yeah, huge news, but I was not
able to get any more shares--it gapped
up like they always do when they show
up in the Journal. The poop is this:
Ariad can control EPO in monkeys, give
the monkey a pill to regulate gene
expression (which is introduced through
AAV, which is a harmless virus).
It is very cutting edge stuff, I like
aria for the long term, but I had to take
4k of losses last year in it, microcap
biotech gets no respect. Everybody wants
internut crap.
I have some of the warrants, ariaw, holding
out that they will do one of those things
where they extend their life--otherwise
I am pretty sure ariaw expire in May.
At 3/16ths they are cheap, but as they
say cheap for a reason.
Rick Harmon who is one of the experts on
ariad sold his shares this morning (his
thread is the t/tif)...which I think sucks,
but probably a good trade.
Who knows, if Aria and Avigen and TGEN and
companies like them threaten AMGN, and certainly
ariads ARGENT technology does for Epogen, maybe
we will see a takeover or something.
--Mike |
